Menu

Rothwell Figg BiosimilarIP Blog

Skip navigation Menu
  • Regulatory
  • Legal
  • News
  • About RFEM
  • Search

Amgen

Random entry RSS

You are here:

  1. Home
  2. Tag Archives: Amgen
  • Posted in:

    • News

    Amgen’s Amgevita Receives Approval in Europe

    By C. Nichole Gifford March 27, 2017 Comments are off

    Amgen’s Amgevita, an adalimumab biosimilar to AbbVie’s Humira®, received approval from the European Commission on March 23, 2017. ...

    Read more

    Tagged with: AbbVie, adalimumab, Amgen, EMA, FDA, Humira®, News, Regulatory

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • Legal

    Sanofi and Regeneron Seek Declaratory Judgment that Dupixent® (Dupilumab) Does Not Infringe Amgen’s Patent

    By C. Nichole Gifford and Seth Cockrum March 22, 2017 Comments are off

    Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. (collectively “Plaintiffs”) filed a Complaint in the...

    Read more

    Tagged with: Amgen, District Court, dupilumab, Dupixent®, Immunex, Legal, Litigation, Regeneron, Sanofi

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • Legal

    Complaint in Genentech v. Amgen Dismissed Without Prejudice

    By Daniel McCallum and C. Nichole Gifford March 2, 2017 Comments are off

    Genentech’s lawsuit against Amgen has come to a quick (although perhaps temporary) end, with the Court dismissing Genentech’s complaint...

    Read more

    Tagged with: Amgen, Avastin®, bevacizumab, BPCIA, District Court, Genentech, Genentech v. Amgen, Legal, Litigation, Patent Dance

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Coherus Files Four IPR Petitions on Humira® Patent

    By C. Nichole Gifford February 1, 2017 Comments are off

    Coherus Biosciences, Inc. (“Coherus”) has filed four petitions with the Patent Trial and Appeal Board (“PTAB”) for inter partes...

    Read more

    Tagged with: adalimumab, Amgen, Coherus, Humira®, Invalidity, IPR, Legal, News, PTAB, USPTO, Validity

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

Pages

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5

Sign Up for Updates

Don’t worry. We don’t spam.

Practice Contacts

  • E. Anthony Figg

  • Joseph A. Hynds

  • Seth Cockrum

Featured Posts

  • U.S. – E.U. Mutual Recognition Agreement Will Reduce Costs

    August 1, 2019

  • House Democrats Seek to Remove Biologics Exclusivity Period From USMCA

    July 25, 2019

  • What Pharma Companies Must Do Globally to Benefit From Canada’s Patent Term Extension Framework

    July 22, 2019

Popular Tags

AbbVie adalimumab Amgen Avastin® bevacizumab Biocon Biogen Boehringer Ingelheim BPCIA Celltrion District Court EMA FDA Featured Federal Circuit Genentech Herceptin® Hospira Humira® Infliximab IPR Janssen Legal Litigation Mylan Neulasta® News Notice Requirement Patent Dance pegfilgrastim Pfizer PTAB Regeneron Regulatory Remicade® Rituxan® Rituximab Roche Samsung Bioepsis Sandoz Sanofi Supreme Court Teva trastuzumab USPTO
Opinions expressed in articles on www.BiosimilarsIP.com are solely those of the author only and do not necessarily reflect the views of Rothwell Figg Ernst & Manbeck, P.C., its clients, or any of its respective affiliates. These materials are for general information purposes only and should not be taken as legal advice per the full disclaimer below.

Contact Us

Email Us
202.783.6040
Our Location

Find Out More

  • About Us
  • Results
  • Careers
  • Practices
  • Publications
  • News & Events
  • Professionals

© 2019 Rothwell, Figg, Ernst & Manbeck, P.C. All Rights Reserved

  • Disclaimer
  • Privacy Policy
Back to Top